Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes : A Preliminary Report

Aims. To measure the effect of pegylated interferon-α therapy on serum activin-A, activin-B, and follistatin and their correlation with viral load and liver fibrosis in chronic hepatitis C (CHC). Methods. This study was cross-sectional and sera were collected from 165 participants classified into 7...

Full description

Saved in:
Bibliographic Details
Published in:Gastroenterology research and practice 2014-01, Vol.2014 (2014), p.1-9
Main Authors: Refaat, Bassem, El-Shemi, Adel Galal, Ashshi, Ahmed Mohamed, AlZanbagi, Adnan
Format: Article
Language:English
Subjects:
Activins
Binding proteins
Care and treatment
Cytokines
Drug dosages
Enzymes
Genetic aspects
Genotype
Health aspects
Hepatitis
Hepatitis C
Interferon
Laboratories
Measurement
Studies
Tumor necrosis factor-TNF
Viremia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims. To measure the effect of pegylated interferon-α therapy on serum activin-A, activin-B, and follistatin and their correlation with viral load and liver fibrosis in chronic hepatitis C (CHC). Methods. This study was cross-sectional and sera were collected from 165 participants classified into 7 groups: 40 healthy negative control, 33 treatment naïve patients as positive control, 19 patients at week 4, 22 at week 12, and 19 at week 24 of treatment initiation and 21 responders and 11 nonresponders at the end of 48-week treatment protocol. Serum candidate proteins were measured using ELISA and liver fibrosis was assessed by AST platelet ratio index (APRI). Results. CHC significantly increased activins and decreased follistatin compared to negative control (P
ISSN:1687-6121
1687-630X
DOI:10.1155/2014/628683